PHARMACEUTICAL COMPANY AstraZeneca will pay $1.1bn to resolve an ongoing transfer pricing dispute over its US business.
The UK-Swedish based firm will pay the $1.1bn net costs to US tax authorities to cover transfer pricing arrangements over a 13-year period from 2002 to the end of 2014, it announced today. It had already announced in February that it will pay £505m to settle a dispute with HM Revenue & Customs.
“AstraZeneca had provided in its accounts for the outcome of these issues, at the heart of which are complex transfer pricing considerations that have taken many years to resolve,” the group said.
It also said that the group’s effective tax rate for 2011 is expected to be approximately six percentage points lower than the previous guidance of 27%, at around 21%.
The accountancy world has reacted to the news that the UK has voted to leave the EU
Deloitte has made a move into the SME market with Propel, a cloud-based, £2.5m accounting services tool
French police have raided Lucamobile's Paris HQ on suspicion of money laundering and tax fraud
European Commission is one step closer to a wide-reaching anti-tax avoidance package